We identified that SGLT2 inhibitor kidney outcome trial participants differed substantially from the real-world English primary care CKD population; trial participants were younger, more likely to have a co-existing T2D and had more advanced kidney disease, with lower eGFR and higher levels of albuminuria, compared with the trial eligible and total CKD primary care populations. This evidence concerns the gene SLC5A2 and chronic kidney disease.